# Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

> **NCT05606471** · PHASE4 · UNKNOWN · sponsor: **University of Nottingham** · enrollment: 45 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus in Obese

## Interventions

- **DRUG:** Semaglutide Pen Injector [Ozempic]
- **DIETARY_SUPPLEMENT:** Very-low Calorie Diet

## Key facts

- **NCT ID:** NCT05606471
- **Lead sponsor:** University of Nottingham
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-15
- **Primary completion:** 2023-07-28
- **Final completion:** 2023-07-28
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05606471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05606471, "Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05606471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*